Pulse Biosciences (NASDAQ:PLSE) posted its earnings results on Sunday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.09), MarketWatch Earnings reports.
Shares of PLSE stock traded down $4.57 during trading hours on Tuesday, hitting $29.88. The company had a trading volume of 3,521 shares, compared to its average volume of 181,818. The firm has a market capitalization of $757.22 million, a price-to-earnings ratio of -13.16 and a beta of 1.88. Pulse Biosciences has a 12 month low of $5.11 and a 12 month high of $45.82. The firm’s fifty day moving average is $32.71 and its 200 day moving average is $18.79.
Separately, HC Wainwright raised their price objective on Pulse Biosciences from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, February 4th.
About Pulse Biosciences
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.
Featured Article: QQQ ETF
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.